Onesource Specialty Pharma share price
NSE: ONESOURCEBSE: 544292Pharmaceuticals & BiotechnologySmall Cap
Onesource Specialty Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2025
Last close ₹1,577.60down ₹12.20 (0.77%)BSE ₹1,573.50
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,589.80.
28 Oct: open ₹1,620.00, high ₹1,642.90, low ₹1,560.00
52-week range of traded prices to 28 Oct 2026
₹1,057.00Low, 30 Jan 2026₹1,925.00High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹18,091 Cr373rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.06
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 0.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹13 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 0.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 38,11,76127.4% delivered
About Onesource Specialty Pharma
OneSource Specialty Pharma is a contract development and manufacturing organisation (CDMO), a company that develops and makes medicines for other drug companies.1 From Bengaluru, it serves pharmaceutical and biotechnology companies in regulated and international markets, in drug-device combinations, biologics, sterile injectables and softgel (soft gelatin capsule) technologies.12
It has 5 plants in Bengaluru, 4 owned and 1 run under a loan licence agreement, with approvals from regulators including the US FDA, EMA, MHRA, Health Canada, TGA, WHO GMP and ANVISA.31 Its workforce is over 1,600 employees.4
It was incorporated in 2007.5 A scheme of arrangement effective 1 Apr 2024 brought Strides' softgel business, Steriscience's injectables business and Stelis Biopharma into the company.6 Its founder and promoter, Arun Kumar, chairs the board as a non-executive director.7 Strides Pharma Science, which develops and markets generic and specialty medicines, shares a common promoter with the company.8
Onesource Specialty Pharma key points
Results
- In the quarter to Jun 2026, revenue was ₹4,490 million, up 37% from a year earlier, and EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹1,233 million, up 39%.9
- In the year to Mar 2026, consolidated revenue was ₹14,216 million against ₹14,449 million a year earlier, and consolidated EBITDA was ₹3,042 million against ₹4,665 million, a margin of 21% against 32%.10
- In the year to Mar 2026, consolidated adjusted profit after tax was ₹739 million, against ₹2,314 million a year earlier; the company presents it excluding one-off items (₹99 million) and amortisation of intangibles from the merger scheme (₹1,378 million) that year.1011
Market position
- In June 2026, more than 40% of generic semaglutide pens sold in India were made at its site, the company said; semaglutide is a diabetes and weight-loss drug.12
- OneSource says it is the only CDMO supporting all 4 generic semaglutide approvals in G7 countries: 3 in Canada and 1 in the US; its 4 May 2026 filing calls the US one tentative (cleared on standards, sale held back until patents or exclusivity end).1314
Service offerings
- Drug-device combinations. Fills injectable drugs and assembles them into devices such as pre-filled syringes and pen injectors, with 12 device platforms and more than 50 drug-device projects.1516
- Biologics. Makes biologic drugs (medicines made in living cells) on microbial and mammalian systems, with drug substance and finished product at one site; its biologics opportunity pipeline grew nearly 4x in the year to Mar 2026.171819
- Sterile injectables. Makes sterile injectables, including freeze-dried (lyophilised) products, with a focus on critical-care injectables that often run short in global markets, and runs a dedicated penicillin plant under US FDA approval.20
- Softgel capsules. Makes soft gelatin capsules; under Strides the business served mainly Strides' own products, and it now offers contract development and manufacturing to other companies.2122
Plants and capacity
- On its earnings call of 25 Jul 2026, the company said its second cartridge-filling line would start commercial production in the quarter to Sep 2026, doubling its sterile days (days a line can run sterile).23
- The company said on the same call that a third line would be ready within the year to Mar 2027, with 675 sterile days expected in the year to Mar 2028.2425
Customers and partners
- In the year to Mar 2026, about 80% of its project wins and licensing deals came from existing customers; it serves more than 80 customers, more than 50 of them on 2 or more projects or products.26
- Partners Dr. Reddy's Laboratories (announced 29 Apr 2026) and Orbicular (4 May 2026) won Canada's first 2 generic semaglutide approvals, copies of Ozempic made by OneSource.2714
- On 11 Feb 2026 it received Saudi approval for its generic semaglutide, to be sold by Hikma Pharmaceuticals, its exclusive partner for the Middle East and North Africa.28
Expansion and capital spending
- The company stated in its annual report for the year to Mar 2026 that about 80% of its 4-year, US$100 million capital spending programme on capacity and technology has been committed.29
- On its earnings call of 25 Jul 2026, the company said it expects its added softgel capacity to be taken up over 12 to 15 months and, with no room at the current site, has started a process to set up a new softgel site.22
- The company said on the same call that it is adding pre-filled syringe and lyophilisation capacity in injectables, shutting 1 sterile injectable site for the work from the quarter to Sep 2026.30
What the company expects
- The company stated in its annual report for the year to Mar 2026 that it targets organic revenue (from its existing businesses) of US$400 million, with a 40% EBITDA margin, in the year to Mar 2028.31
- On its earnings call of 25 Jul 2026, the company said commercial revenue from many of its new biologics customers would start in the year to Mar 2029, with development contracts before that.32
Recent events
- On 17 Aug 2026, India Ratings upgraded the long-term credit rating (its view of the ability to repay debt) on the company's bank loans to IND A with a Positive outlook, from IND A-.33
- A US FDA inspection of the Sterile Product Division plant in Bengaluru, 22 Jun 2026 to 30 Jun 2026, ended with 1 observation (a finding the company must answer); its documents give no outcome.34
- On 13 May 2026, the board decided not to pursue, in its current form, the acquisition of Steriscience's European contract development and manufacturing business and Brooks Steriscience's anti-infective business.35
Last updated
All 35 sources, each with its page
- 1. Annual report, 31 Aug 2026, page 137
- 2. Annual report, 31 Aug 2026, page 32
- 3. Annual report, 31 Aug 2026, page 190
- 4. Annual report, 31 Aug 2026, page 146
- 5. Annual report, 31 Aug 2026, page 162
- 6. Annual report, 31 Aug 2026, page 6
- 7. Annual report, 31 Aug 2026, page 184
- 8. Annual report, 31 Aug 2026, page 418
- 9. Earnings call, 25 Jul 2026, page 3
- 10. Annual report, 31 Aug 2026, page 145
- 11. Annual report, 31 Aug 2026, page 60
- 12. Earnings call, 25 Jul 2026, page 3
- 13. Annual report, 31 Aug 2026, page 55
- 14. Exchange filing, 4 May 2026, page 2
- 15. Annual report, 31 Aug 2026, page 142
- 16. Annual report, 31 Aug 2026, page 26
- 17. Annual report, 31 Aug 2026, page 24
- 18. Earnings call, 25 Jul 2026, page 11
- 19. Annual report, 31 Aug 2026, page 55
- 20. Annual report, 31 Aug 2026, page 28
- 21. Annual report, 31 Aug 2026, page 144
- 22. Earnings call, 25 Jul 2026, page 5
- 23. Earnings call, 25 Jul 2026, page 4
- 24. Earnings call, 25 Jul 2026, page 14
- 25. Earnings call, 25 Jul 2026, page 15
- 26. Annual report, 31 Aug 2026, page 34
- 27. Exchange filing, 29 Apr 2026, page 2
- 28. Exchange filing, 11 Feb 2026, page 2
- 29. Annual report, 31 Aug 2026, page 64
- 30. Earnings call, 25 Jul 2026, page 6
- 31. Annual report, 31 Aug 2026, page 62
- 32. Earnings call, 25 Jul 2026, page 9
- 33. Exchange filing, 18 Aug 2026, page 2
- 34. Exchange filing, 2 Jul 2026, page 1
- 35. Annual report, 31 Aug 2026, page 148
Results
Consolidated; ₹ crore.Onesource Specialty Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +10.7%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −103.9%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹516 Crup 14.97%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹57 Crup 129.96%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 11.1%
Revenue by quarter
Peak revenue ₹516 Cr, quarter to Sep 2026; lowest ₹290 Cr, quarter to Dec 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 3 of the 8 quarters shown
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 393 | 426 | 327 | 376 | 290 | 428 | 449 | 516 |
| Net profit | −69 | 98 | 0 | 10 | −89 | 5 | 25 | 57 |
| Net margin | −17.5% | 23.1% | −0.1% | 2.8% | −30.6% | 1.1% | 5.6% | 11.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,422 Crdown 1.61%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹74 CrYear to Mar 2025: −₹18 Cr
- Net margin
- −5.2%
Revenue by year
Peak revenue ₹1,445 Cr, year to Mar 2025; lowest ₹1,422 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 1,445 | 1,422 |
| Net profit | −18 | −74 |
| Net margin | −1.2% | −5.2% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharma, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.Onesource Specialty Pharma PE ratio and valuation
Price to book
At or below today's level on 39% of 247 trading days over the last year.
LowestHighest
Its median3.14Industry median2.94
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −15.9% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
93 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 46 of the 53 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 93 funds holding Onesource Specialty Pharma
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 5
- AddedAdded. Funds that held more shares than at the end of the month before.
- 21
- CutCut. Funds that held fewer shares than at the end of the month before.
- 32
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 35
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal Large and Midcap FundMotilal Oswal Mutual Fund | 37,21,818 | 2.86% | ₹566.3 Cr |
| Motilal Oswal Flexi cap FundMotilal Oswal Mutual Fund | 23,91,230 | 2.71% | ₹363.8 Cr |
| Motilal Oswal ELSS Tax Saver FundMotilal Oswal Mutual Fund | 10,90,000 | 3.39% | ₹165.9 Cr |
 360 ONE Focused Fund360 One Mutual Fund | 10,57,754 | 2.48% | ₹160.9 Cr |
 Axis Small Cap FundAxis Mutual Fund | 9,16,559 | 0.45% | ₹139.5 Cr |
 Mirae Asset Healthcare FundMirae Asset Mutual Fund | 6,91,867 | 3.01% | ₹105.3 Cr |
| Axis Flexi Cap FundAxis Mutual Fund | 6,01,287 | 0.69% | ₹91.5 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 5,46,302 | 0.23% | ₹83.1 Cr |
| Motilal Oswal Small Cap FundMotilal Oswal Mutual Fund | 5,03,076 | 0.92% | ₹76.5 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 4,85,952 | 0.26% | ₹73.9 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Onesource Specialty Pharma insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group6 purchases, 0 sales₹45 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹45 Cr50 pledge filings of unclear kind
- Others: no market trade · 4 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Onesource Specialty Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Onesource Specialty Pharma in market cap.Healthcare companies
Onesource Specialty Pharma is not on the chart: it has no P/E today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Neuland LaboratoriesNEULANDLAB | 25,621 | 51.47 | 13.67 | +78.3% | +182.6% | 29.3% | 32.1% | 0.17% |
 Granules IndiaGRANULES | 22,926 | 34.61 | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.21% |
 Shilpa MedicareSHILPAMED | 18,228 | 61.31 | 7.03 | +27.9% | +167.6% | 12.0% | 10.9% | 0.06% |
 Cohance LifesciencesCOHANCE | 18,214 | 171.45 | 4.66 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Caplin Point LaboratoriesCAPLIPOINT | 17,960 | 26.99 | 5.01 | +15.0% | +17.7% | 20.7% | 19.8% | 0.34% |
 Alivus Life SciencesALIVUS | 17,181 | 28.49 | 5.16 | +7.9% | +21.7% | 19.6% | 22.7% | 0.36% |
 PfizerPFIZER | 17,084 | 23.24 | 4.06 | +10.7% | −9.1% | 17.5% | 21.0% | 2.01% |
 Eris LifesciencesERIS | 16,307 | 23.05 | 3.93 | +11.1% | +70.2% | 19.6% | 13.4% | 0.61% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Onesource Specialty Pharma announcements
Oct 2026
27 Oct · Management
21 Oct · Analysts
Onesource Specialty Pharma share price by year
Each calendar year to 2025.Onesource Specialty Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,810.60 | – | 2,197.80 | 1,238.20 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 24 Jan 2025.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,402.70 | 1,605.00 | 1,384.10 | 1,589.80 | 1,568.76 | 78,03,594 | 16.2% |
| 26 Oct 2026 | 1,334.10 | 1,404.50 | 1,326.10 | 1,397.30 | 1,379.37 | 2,28,373 | 63.8% |
| 23 Oct 2026 | 1,377.80 | 1,377.80 | 1,320.60 | 1,334.10 | 1,341.28 | 2,06,529 | 63.5% |
| 22 Oct 2026 | 1,358.00 | 1,385.30 | 1,326.30 | 1,377.80 | 1,360.03 | 1,08,051 | 41.8% |
| 21 Oct 2026 | 1,365.70 | 1,385.00 | 1,331.30 | 1,357.10 | 1,364.20 | 2,16,713 | 63.1% |
| 19 Oct 2026 | 1,412.90 | 1,413.30 | 1,352.30 | 1,366.60 | 1,382.15 | 92,387 | 44.7% |
| 16 Oct 2026 | 1,448.40 | 1,448.40 | 1,401.90 | 1,407.80 | 1,418.26 | 1,03,563 | 45.2% |
| 15 Oct 2026 | 1,440.00 | 1,442.00 | 1,421.10 | 1,433.20 | 1,430.98 | 85,979 | 42.4% |
| 14 Oct 2026 | 1,459.10 | 1,460.00 | 1,423.90 | 1,442.40 | 1,442.17 | 3,03,380 | 64.5% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ONESOURCE
- BSE code
- 544292
- ISIN
- INE013P01021
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.onesourcecdmo.com
- CIN
- L74140MH2007PLC432497
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2007
- Registered office
- 201, Devavrata, Sector 17,Vashi, Sanpada, Thane, Navi Mumbai 400703, Maharashtra
- Share registrar
- Integrated Registry Management Services Pvt. Ltd (Integrated Enterprises (India) Ltd)
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap